莫西沙星和奈替米星联合方案治疗耐多药肺结核的近期疗效观察

Short-term therapeutic effect of moxifloxacin and netilmicin On multidrug resistant pulmonary tuberculosis

目的评价含莫西沙星和奈替米星联合化疗方案对耐多药肺结核(MDR-PTB)的疗效。方法将56例MDR-PTB患者随机分为两组,治疗组28例采用以莫西沙星(M)和奈替米星(N)为主,联合力克肺疾(D)、丙硫异烟胺(Pt)、吡嗪酰胺(Z);对照组28例采用以左氧氟沙星(V)和阿米卡星(A)为主,联合D、Pt、Z;疗程均为21个月。结果:治疗组痰菌阴转率92.9%,对照组痰菌阴转率67.9%,治疗组明显高于对照组(P<0.05)。结论含莫西沙星和奈替米星方案治疗耐多药肺结核有助于痰菌阴转和病灶吸收,药物不良反应低,值得在临床推广应用。

Objective To evaluate the therapeutic effect of moxifloxacin （M） and netilmicin （N） On multidru resistant pulmona- ry tuberculosis （MDR-PTB）. Methods 56 cases of MDR-PTB were randomly divided into two qroups ： 28 cases in the trial groyp [ trea- ted with M, N, D（ pasiniazid）, Pt（ prothionamide）, Z（ pyrazinop yrimidines） ] ,28 cases in the controlled group [ treated with V（ levofloxa- cin）, A （amyxin） , D, Pt, Z ]. The treatment course was 21 months. Results The sputum smear negative conversion rate was 92.9% and 67.9% respectively in the trial group and control group （ P 〈 0.05 ）. Conclusion The regimen containing moxifloxacin and netilmiein was helpful to the sputum smear negative conversion and the absorption of the athology with few adverse reaction. It should be popularized in the practice.